CagriSema: what the REDEFINE program actually showed

CagriSema is a bet on two appetite pathways instead of one. It pairs cagrilintide, a long-acting amylin analog, with semaglutide, the familiar GLP-1 agonist, in a single weekly injection. The theory is complementary biology — amylin and GLP-1 suppress appetite through different mechanisms, so combining them might add up to more than either alone. The REDEFINE Phase 3 program is where that theory met data, and the result was more nuanced than the early hype.

The building blocks

Each half has its own evidence base. In a Phase 2 trial, cagrilintide alone produced dose-dependent weight loss in people with overweight or obesity, establishing amylin agonism as a viable weight-management lever.^[1] A separate Phase 1b study showed the two could be co-administered safely with a pharmacokinetic and tolerability profile supporting a fixed-dose combination.^[2] Those studies justified building the combination — but combination logic does not guarantee additive results, which is exactly what Phase 3 had to test.

REDEFINE 1: obesity without diabetes

REDEFINE 1 randomized adults with overweight or obesity (without type 2 diabetes) to CagriSema, its individual components, or placebo. The combination produced substantial mean weight loss clearly exceeding placebo over the trial.^[3] The widely discussed wrinkle was that the topline figure landed below some pre-trial expectations — in part because many participants did not reach the highest target dose — which tempered the “step-change” narrative even as the absolute weight loss remained large and clinically meaningful. A secondary analysis from REDEFINE 1 also reported reductions in blood pressure with CagriSema, consistent with the broader cardiometabolic effects seen across this drug class.^[4]

REDEFINE 2: when type 2 diabetes is in the mix

REDEFINE 2 tested CagriSema in adults who had both overweight/obesity and type 2 diabetes — a population that typically loses less weight on incretin therapy. The combination again produced significantly greater weight loss than placebo, alongside glycemic improvement, in this harder-to-treat group.^[5] That the effect held up in a diabetes population is a meaningful data point, even though the magnitude in such populations is generally more modest than in people without diabetes.

The honest caveats

A few things keep this precise. The tolerability profile is the GLP-1-class profile — gastrointestinal side effects were common and dose-dependent, and the share of participants reaching the top dose shaped the headline numbers. CagriSema does not yet have the long-term cardiovascular-outcomes evidence that anchors injectable semaglutide's case; REDEFINE measured weight and metabolic endpoints, not multi-year hard outcomes. And its regulatory status is a moving target — what it is approved for, and when, is for regulators to decide on the full dataset, not for a press cycle.

The honest bottom line

CagriSema works: pairing amylin and GLP-1 agonism produces large, real weight loss across the REDEFINE Phase 3 trials, in people with and without diabetes. The honest framing is that it landed as a strong combination rather than the runaway leap some expected — the dosing-uptake detail matters, and the long-term outcomes question is still open. As emerging Phase 3 evidence, it is genuinely promising; as a settled verdict, it is not there yet.